Print Issue: August 01, 2008

Experimental Drug Benefits Type 2 Diabetics

SAN FRANCISCO—New results from a phase III trial demonstrate that the investigational once-weekly formulation of exenatide, an incretin mimetic agent, provides sustained glucose control and weight loss for at least 52 weeks in patients with type 2 diabetes.

Even Brief Lithium Exposure Can Harm

WASHINGTON, D.C.—Impaired renal function is a well-known side effect of lithium, which has been used since the 1950s to treat acute episodes of mania and as maintenance therapy for bipolar disorder. In the largest study to date of the renal effects of lithium, researchers found that the duration of lithium treatment did not correlate with glomerular filtration rate (GFR).

Bladder Trauma in Iraqi Civilians Examined

ORLANDO—Penetrating injuries from bullets or metal fragments from explosive devices are the most common cause of civilian bladder trauma in Iraq, according to Firas Ghanim Petros, MD, and his colleagues at Al Yarmouk Teaching Hospital, a major trauma center in Baghdad.

In Clinical Trials, Does One Size Fit All?

Practicing evidence-based medicine can be difficult in nephrology, where randomized controlled trials are few and far between. In general, the more that trials use hard outcomes such as morbidity and mortality, the greater our confidence that the therapies will have an impact on patients’ lives. Using end points such as these, however, often require large sample sizes.

Beta Blocker Meets Stricter Criterion

NEW ORLEANS—Two pooled analyses of the newest beta blocker, nebivolol, demonstrate that it is effective as once daily monotherapy in stage 1 and 2 hypertension using more stringent criteria than normal to measure BP control.

Next post in News